---
title: "Vera Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285541707.md"
datetime: "2026-05-07T11:33:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285541707.md)
  - [en](https://longbridge.com/en/news/285541707.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285541707.md)
---

# Vera Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -1.69, missing the estimate of USD -1.365.

#### Financial Results for the Quarter Ended March 31, 2026

-   Vera Therapeutics, Inc. reported a net loss of - $121.0 million for the quarter ended March 31, 2026, compared to a net loss of - $51.7 million for the same period in 2025.
-   Net cash used in operating activities was - $106.5 million for the quarter ended March 31, 2026, compared to - $54.4 million for the same period in 2025.
-   Research and development expenses were $86,011 thousand for the three months ended March 31, 2026, up from $41,278 thousand for the three months ended March 31, 2025.
-   General and administrative expenses were $39,121 thousand for the three months ended March 31, 2026, compared to $15,916 thousand for the three months ended March 31, 2025.
-   Total operating expenses amounted to $125,132 thousand for the three months ended March 31, 2026, versus $57,194 thousand for the three months ended March 31, 2025.
-   Loss from operations was - $125,132 thousand for the three months ended March 31, 2026, compared to - $57,194 thousand for the three months ended March 31, 2025.
-   Other income, net, was $4,100 thousand for the three months ended March 31, 2026, down from $5,500 thousand for the three months ended March 31, 2025.
-   The change in unrealized gain/loss on marketable securities was - $942 thousand for the three months ended March 31, 2026, compared to $261 thousand for the three months ended March 31, 2025.
-   Comprehensive loss was - $121,974 thousand for the three months ended March 31, 2026, versus - $51,433 thousand for the three months ended March 31, 2025.

#### Balance Sheet as of March 31, 2026

-   Vera Therapeutics, Inc. reported $596,760 thousand in cash, cash equivalents, and marketable securities as of March 31, 2026, compared to $714,589 thousand as of December 31, 2025.
-   Total assets were $621,739 thousand as of March 31, 2026, compared to $734,733 thousand as of December 31, 2025.
-   Total liabilities were $122,042 thousand as of March 31, 2026, compared to $130,212 thousand as of December 31, 2025.
-   Total stockholders’ equity was $499,697 thousand as of March 31, 2026, compared to $604,521 thousand as of December 31, 2025.
-   The accumulated deficit was - $881,897 thousand as of March 31, 2026, compared to - $760,865 thousand as of December 31, 2025.

#### Outlook / Guidance

-   The U.S. Food and Drug Administration (FDA) granted priority review to the Biologics License Application (BLA) for atacicept, with a Prescription Drug User Fee Act (PDUFA) date of July 7, 2026.
-   Vera Therapeutics, Inc. is on track for a U.S. commercial launch of atacicept in mid-2026, pending regulatory approval.
-   The company’s strong balance sheet is expected to be sufficient to fund operations beyond potential atacicept approval and U.S. commercial launch.

### Related Stocks

- [VERA.US](https://longbridge.com/en/quote/VERA.US.md)

## Related News & Research

- [UBS Group AG Boosts Position in Vera Therapeutics, Inc. $VERA](https://longbridge.com/en/news/286643383.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md)
- [OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 | OSTX Stock News](https://longbridge.com/en/news/286607728.md)